Overview Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland Carcinomas Status: Recruiting Trial end date: 2024-06-01 Target enrollment: Participant gender: Summary The objective is to investigate the efficacy and safety of Surufatinib Neoadjuvant Therapy for Locally Advanced Primary Saliary Gland Adenocarcinoma. Phase: N/A Details Lead Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University